Orforglipron
Orforglipron (Foundayo): the GLP-1 pill approved in April 2026, what it is approved for and how it differs from injectable GLP-1 drugs.
FDA-approved · Evidence grade A · Reviewed
Orforglipron (Foundayo). Oral GLP-1 receptor agonist (not a peptide).
AFDA-approved. Evidence grade A: approved, large human trials.
What is Orforglipron?
Orforglipron is a GLP-1 drug taken as a daily pill. Unlike semaglutide it is a small molecule, not a peptide.
Is Orforglipron FDA-approved?
Approved on April 1, 2026 as Foundayo for weight management. An FDA decision on type 2 diabetes is expected in late 2026.
What does the evidence show for Orforglipron?
Large human trials. Average weight loss in trials was up to about 11% over 72 weeks, which is less than the leading injectables.
What are the known risks of Orforglipron?
All approved GLP-1 drugs carry a boxed warning about thyroid C-cell tumors. Stomach and bowel side effects are the most common.
How is Orforglipron measured?
A tablet, so there is nothing to draw or calculate.
Sources: Managed Healthcare Executive: GLP-1 pills; GoodRx: GLP-1 trends; Ro: do GLP-1 pills work. This profile does not recommend any dose or use.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.